

HARTMANN USA Expands Advanced Wound Care Portfolio Through Exclusive Distribution Agreement with SweetBio®

Agreement expands clinician and patient access to SweetBio's innovative collagen and Mānuka honey technology to clinicians through HARTMANN's national commercial organization

ROCK HILL, S.C., October 1st, 2026 – HARTMANN USA, Inc. announced an exclusive national commercial distribution agreement with SweetBio®, a biotechnology company pioneering bioengineered wound care solutions. Through the agreement, HARTMANN USA will become the exclusive nationwide commercial distribution partner for VERIS™, SweetBio®'s advanced wound care product. VERIS™ is intended for the management of acute and chronic wounds and uniquely features collagen derivative and Mānuka honey in a patented formulation.

The agreement expands HARTMANN's advanced wound care portfolio with a clinically differentiated solution designed to support wound healing while providing clinicians and patients with a simple and effective treatment option. Through HARTMANN's established commercial infrastructure and national sales organization, clinicians across the United States will gain expanded access to VERIS™.

"HARTMANN is committed to providing clinicians with evidence-based solutions that improve patient outcomes and address evolving wound care needs," said Jon Procopio, Managing Director HARTMANN USA. "VERIS™ complements our existing advanced wound care portfolio with an innovative collagen and Mānuka honey technology that offers clinicians another option to support wound healing. We are excited to partner with SweetBio and expand access to this unique solution."

SweetBio's patented MX® technology combines collagen derivative, Mānuka honey, and hydroxyapatite into a single bioengineered wound care solution. The collaboration brings together SweetBio's innovative technology and HARTMANN's clinical expertise, customer relationships, and national reach.

"We are proud to partner with HARTMANN, a company recognized for its leadership in wound care and dedication to improving patient outcomes," said Kayla Rodriguez Graff, Founder and CEO of SweetBio. "From the beginning, SweetBio's mission has been to make innovative, high-performing wound care technologies more accessible to patients. "HARTMANN's strong customer relationships, clinical expertise, and nationwide reach make them the ideal partner to help expand access to VERIS™ and bring our technology to more clinicians, care settings and patients across the country."

Distribution of VERIS™ through HARTMANN USA will begin on November 1, 2026.

About HARTMANN USA

HARTMANN USA, Inc. is part of the global HARTMANN GROUP, a leading provider of advanced wound care and skin integrity solutions with a legacy spanning more than 200 years, beginning with the world's first absorbent wound dressing. HARTMANN delivers proven healthcare solutions that work, designed to be easy to use, clinically effective, and cost-efficient. Guided by values of excellence, customer focus, and teamwork, HARTMANN USA represents a commitment to improving healthcare outcomes and supporting professionals across the continuum of care.

About SweetBio

Founded in 2015, SweetBio® is a Memphis-based biotechnology company dedicated to advancing wound care by bridging the gap between clinical performance and affordability. SweetBio's initial products—VERIS™ and APIS®—provide clinicians with a simple and effective solution to support patient recovery. Both VERIS™ and APIS® are powered by SweetBio's patented combination of collagen and Mānuka honey, delivering industry-leading clinical outcomes. SweetBio® products are FDA-cleared, Medicare-covered, and supported by peer-reviewed publications. For more information visit sweetbio.com and follow along on Instagram and LinkedIn.